3Vanden LS,Valkenburg HA,Cats A.Evaluation of diagnostic criteria for ankylosing spondylitis:a proposal for modification of the New York criteria[J].Arthritis Rheum,1984,27(4):361-368.
2Rowland TL,McHugh SM,Deighton J,et al.Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells.Immunopharmacology,1998,40:11-20.
3Laasila K,Leirisalo-Repo M.Side effects of sulphasalazine in patients with rheumatic diseases of inflammatory bowel disease.Scand J Rheumatol,1994,23:338-340.
4Clegg DO,Reda DJ,Weisman MH.Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis:a Department of Veterans Affairs Cooperative Study.Arthritis Rheum,1996,39:2004-2012.
5Bennett PH,Berch TA.New York symposium on population studies in the rheumatic disease:new diagnostic criteria.Bull Rheum Dis,1967,17:453-458.
6Rowland TL,McHugh SM,Deighton J.Selective down-regulation of T cell-and non-T cell-derived tumour necrosis factor alpha by thalidomide:comparisons with dexamethasone.Immunol Lett,1999,68:325-332.
7Breban M,Gombert B,Amor B.Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis.Arthritis Rheum,1999,42:580-581.
9Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selec- tively inhibits tumor necrosis factor alpha production by stimulated human monocytes[J]. J Exp Med, 1991, 193(3): 699-703.
10van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. Aproposal for modification of the New York criteria[J]. Arthritis Rheum, 1984, 27(4):361-368.
